Received May 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y | — |
A 2 month old patient may have received a Gardasil 9 vaccine.; No adverse experience reported by patient; This Spontaneous report was received from a health professional and referred to a 2 month patient of unknown gender. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant medication. The reporter stated that while performing a monthly vaccine reconciliation count it was discovered that the patient might have received a human papillomavirus 9-valent vaccine (GARDASIL 9) (Product administered to patient of inappropriate age) first dose, lot number Y and expiration date of 04-Nov-2026 for prophylaxis (dose, route of administration and anatomical location were not reported). The Staff documented that a Pneumococcal 20-valent Conjugate Vaccine (PREVNAR 20) was administered, but the lot number recorded in the patient's electronic chart and facility logbook was that of a human papillomavirus 9-valent vaccine (GARDASIL 9) vaccine and not a Pneumococcal 20-valent Conjugate Vaccine (PREVNAR 20) vaccine. It is unclear what was actually given. Staff was questioned, but could not recall details of this event. The Patient's parents had not reported any adverse events.